← Back to Search

Other

IMG-007 for Atopic Dermatitis/Eczema

Phase 1 & 2
Waitlist Available
Research Sponsored by Inmagene LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female aged ≥ 18 and < 75 years
Documented history of inadequate response or lack of tolerability to a stable regimen of one or more topical treatment before the Screening visit, or for whom topical treatments are otherwise inadvisable
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 24
Awards & highlights

Study Summary

This trial looks at the safety of a new drug for adults with moderate-to-severe atopic dermatitis.

Who is the study for?
Adults aged 18-75 with moderate-to-severe Atopic Dermatitis (AD) who haven't responded well to topical treatments can join this trial. Participants must not be pregnant or breastfeeding and agree to use effective contraception. Those with active infections, TB, hepatitis B/C, HIV, or other skin conditions that could affect the study's results are excluded.Check my eligibility
What is being tested?
The trial is testing IMG-007 against a placebo in adults with AD. It aims to check how safe IMG-007 is, how the body processes it (pharmacokinetics), and if it's effective in improving symptoms of AD.See study design
What are the potential side effects?
While specific side effects for IMG-007 aren't listed here, common ones for new AD treatments may include skin irritation at the application site, headaches, cold-like symptoms and possible allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 75 years old.
Select...
Topical treatments have not worked for me or I cannot use them.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluation of Adverse Events in Participants
Secondary outcome measures
Evaluation of Eczema Area and Severity Index (EASI)
Pharmacokinetic Characterization

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: IMG-007 Dose 2Experimental Treatment1 Intervention
IMG-007 Dose 2 will be administered intravenously 3 times over 4 weeks
Group II: IMG-007 Dose 1Experimental Treatment1 Intervention
IMG-007 Dose 1 will be administered intravenously 3 times over 4 weeks
Group III: PlaceboPlacebo Group1 Intervention
Placebo will be administered intravenously 3 times over 4 weeks

Find a Location

Who is running the clinical trial?

Inmagene LLCLead Sponsor
5 Previous Clinical Trials
195 Total Patients Enrolled

Media Library

IMG-007 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05984784 — Phase 1 & 2
Eczema Research Study Groups: Placebo, IMG-007 Dose 1, IMG-007 Dose 2
Eczema Clinical Trial 2023: IMG-007 Highlights & Side Effects. Trial Name: NCT05984784 — Phase 1 & 2
IMG-007 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05984784 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Under what qualifications do applicants need to meet in order to be included in this research project?

"Eligibility criteria for this research study are atopic dermatitis and an age between 18 and 74 years old. This clinical trial is currently recruiting 24 subjects in total."

Answered by AI

How many individuals are being monitored in the current experiment?

"Affirmative, the information hosted on clinicaltrials.gov attests to this study's ongoing recruitment efforts. It was first advertised on August 1st 2023 and has been consecutively updated since then. Specifically, 24 patients need to be recruited from 3 distinct sites."

Answered by AI

Is there available capacity for prospective participants in this clinical trial?

"Yes, the information on clinicaltrials.gov reveals that this experiment is actively recruiting participants with an initial posting date of August 1st 2023 and a recent update from August 2nd 2023. A total of 24 individuals will be enrolled at 3 distinct sites."

Answered by AI

Is there an age limit for individuals participating in this experiment?

"This clinical trial is limited to individuals between 18 and 74 years of age. However, there are 94 trials for minors and 162 studies with participants older than 65."

Answered by AI

Who else is applying?

What site did they apply to?
Central Sooner Research
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
2023. "A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05984784.
All > Seborrheic Dermatitis > Atopic Dermatitis
~29 spots leftby Feb 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top